PharmaDrug (BUZZ.C) passed their potential cancer fighter, cepharanthine02HC1, the active ingredient in their oral drug PD-001, through preclinicals today. The results of the test are good. It’s proven…
Pharmaceuticals
Lexaria Bioscience (LEXX.Q) announced today that its DehydraTECH™ technology has been embraced by consumer brands and is now available for sale in over 7,000 stores across the US. “Lexaria’s…
Back in January of this year, we told you about a psychedelics company that was going to come at that sector like many had talked about, but few had…
Lexaria Bioscience (LEXX.Q) announced today that dosing has been completed for its HYPER-H21-2 study, the Company’s second human clinical study of 2021. Hypertension, also known as high blood…
Oragenics Inc. (OGEN.NYSE) announced today that it has entered into a licensing agreement with the National Research Council of Canada (NRC). “With respect to our potential future competitive positioning…
Iterum Therapeutics (ITRM.Q) announced today that it has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its New Drug Application (NDA). Iterum…
Tyme Technologies (TYME.Q) announced today that the United States Patent and Trademark Office has granted the Company additional patent claims related to the Company’s metabolomic technology platform. …
Acorda Therapeutics (ACOR.Q) announced today that it has entered into a distribution and supply agreement with Esteve Pharmaceuticals to commercialize INBRIJA® 33 mg in Spain. “We are…
Aprea Therapeutics (APRE.Q) today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML. “The…
Lexaria Bioscience (LEXX.Q) announced today that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The VIRAL-A20-3 study was performed using Sprague-Dawley rats, with…